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For stem cell therapy to become a routine reality, one of the major challenges to overcome is their storage
and transportation. Currently this is achieved by cryopreserving cells utilising the cryoprotectant
dimethyl sulfoxide (Me2SO). Me2SO is toxic to cells, leads to loss of cell functionality, and can produce
severe side effects in patients. Potentially, cells could be frozen using the cryoprotectant trehalose if it
could be delivered into the cells at a sufficient concentration. The novel amphipathic membrane perme-
abilising agent PP-50 has previously been shown to enhance trehalose uptake by erythrocytes, resulting
in increased cryosurvival. Here, this work was extended to the nucleated human cell line SAOS-2. Using
the optimum PP-50 concentration and media osmolarity, cell viability post-thaw was 60 ± 2%. In addition,
the number of metabolically active cells 24 h post-thaw, normalised to that before freezing, was found to
be between 103 ± 4% and 91 ± 5%. This was found to be comparable to cells frozen using Me2SO. Although
reduced (by 22 ± 2%, p = 0.09), the doubling time was found not to be statistically different to the non-fro-
zen control. This was in contrast to cells frozen using Me2SO, where the doubling time was significantly
reduced (by 41 ± 4%, p = 0.004). PP-50 mediated trehalose delivery into cells could represent an alterna-
tive cryopreservation protocol, suitable for research and therapeutic applications.
 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
In recent years, the developed world has seen an increase in de-
mand for tissue replacement. While the number of donor organs
and operations has remained relatively static, the number of pa-
tients on the transplant waiting list for kidney, pancreas, heart,
lung, and liver has increased [31]. It is hoped that regenerative
medicine, including stem cell-based therapies, could meet this
need, as well as providing novel treatments for currently incurable
conditions [39].
For stem cell-based therapies to be used routinely in a clinical
setting, these cells must be stored and transported. Currently this
need is met through cryopreservation, often using the cryoprotec-
tant dimethyl sulfoxide (Me2SO). However, the viability of both
adult and embryonic stem cells has been found to be significantlydecreased by cryopreservation using Me2SO [20,42]. Perhaps more
seriously, the functionality of cells can be adversely affected. For
example, Katkov et al. [20] found that only 5–10% of human
embryonic stem cells (hESCs) expressed the transcription factor
Oct-4, a marker of pluripotency, following Me2SO cryopreserva-
tion. This property of facilitating the loss of hESCs pluripotency
has been utilised in hESC differentiation protocols [14]. Cryopres-
ervation using Me2SO may also have contributed to the failure of
a phase III clinical trial using human mesenchymal stromal cells,
due to loss of cell viability and functionality [17]. Indeed, it has
been found that the genome-wide DNA methylation profiles of
cells can be altered by Me2SO [40].
In addition, patients may experience severe side effects from
Me2SO toxicity after cells preserved in this cryoprotectant are
transplanted. These include cardiac arrest, severe respiratory ar-
rest, severe neurotoxicity and epileptic seizures [12]. These side ef-
fects are thought to occur in one in 70 patients following
autologous bone marrow transplantation [44]. Although this issue
could be overcome by washing cells prior to implantation, this in-
creases the complexity of the cell delivery method and could
result in significant cell losses. Therefore there is a demand for
Me2SO-free cryopreservation techniques, utilising non-toxic
cryoprotectants, which maintain cell viability and functionality.
306 D.M.C. Sharp et al. / Cryobiology 67 (2013) 305–311The non-permeating cryoprotectant trehalose may provide an
alternative, however to provide maximum protection to the cells,
the trehalose should be present on both sides of the cell membrane
[15]. Recently, the amphipathic membrane permeabilising poly-
mer PP-50 has been used to load human erythrocytes with treha-
lose, which led to a significant enhancement in cryosurvival [27].
PP-50, which can be removed from cell membranes by a small
change in pH [26], is thought to be non-cytotoxic [11,22]. This is
in stark contrast to previous studies using pore-forming bacterial
toxins [1,6,15], where serious health concerns have been raised
regarding the use of these proteins [32,41].
A number of alternative methods for the delivery of trehalose
into cells have previously been employed [4,5]. These include the
use of the ATP receptor channel P2X7 [7,8], prolonged cell culture
[19] or endocytosis [18,30,33]. Stimulation of the P2X7 channel
may lead to apoptosis, necrosis [2] or even neoplasia [3]. The latter
two methods also have the disadvantage of requiring incubation
times of 24 h or more. This is in contrast to the proposed method
of PP-50 mediated trehalose delivery [27].
In the current study, the techniques for the cryopreservation of
cells using trehalose and PP-50 developed by Lynch et al. [27] were
extended to successfully preserve nucleated human cells. The Hu-
man osteosarcoma derived cell line SAOS-2 [16,35] was used as a
model for nucleated, adherent human cells.
Methods and materials
Materials
Unless otherwise stated, all reagents were purchased from Sig-
ma–Aldrich (UK). Materials for the PP-50 polymer synthesis were
sourced as previously described [25]. Foetal bovine serum (FBS),
L-glutamine, and penicillin/streptomycin were purchased from
Invitrogen (UK). Dulbecco’s Phosphate-Buffered Saline (DPBS),
10  DPBS and trypsin–EDTA were purchased from Life Technolo-
gies™ (UK). The CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay (MTS) was purchased from Promega (UK). The SAOS-2
cells were purchased from the European Collection of Cell Cultures.
The Annexin V-FITC Apoptosis Detection Kit was purchased from
BD Biosciences (UK).
PP-50 synthesis and characterisation
The synthesis and characterisation of the PP-50 polymer were
as previously described by Lynch et al. [25].
Cell culture
SAOS-2 cells were grown in tissue culture flasks containing
‘‘growth media’’: Dulbecco’s Modified Eagle’s Medium – high glu-
cose (DMEM), supplemented with 10% (v/v) FBS, L-glutamine
(2 mM), penicillin (100 IU/ml) and streptomycin (100 lg/ml). At
approximately 70% confluency, the cells were subcultured with
trypsin (0.05% w/v) and EDTA (0.02% w/v), and were subsequently
split at a ratio of 1:6. The cells were maintained in a humidified
incubator at 37 C with 5% CO2. The cells were used between pas-
sages 4 and 20.
Calcein and propidium iodide fluorescence assay
Calcein, which is membrane impermeable, was used as a tracer
for hydrophilic species delivery into the cells. The viability of the
cells was assessed using propidium iodide (PI) staining.
SAOS-2 cells were seeded into 35 mm glass bottom culture
dishes (PAA, UK) at 2  105 cells/dish, in growth media. After
48 h of incubation in a humidified incubator at 37 C with 5%CO2, a positive control for PI staining was prepared by fixation with
paraformaldehyde solution (4% w/v, in DPBS) for 10 min, followed
by washing (3) with DPBS.
For the remaining dishes, the cells were washed twice with
DPBS. Afterwards, the cells were incubated for 4 h in serum-free
media supplemented with 0.2 M trehalose, 2 mM calcein, and with
or without PP-50 (200 lg/ml), at pH 7.05. The cells were washed
twice with DPBS, and incubated with growth media containing
Hoechst 33342 (2 lg/ml) and PI (2 lg/ml) for 15 min. Following
three washes with DPBS, the cells were imaged using a TCS SP5 in-
verted laser scanning confocal microscope (Leica, Germany).
PP-50 toxicity
SAOS-2 cells were seeded into 96-well tissue culture plastic
plates (Corning, UK) at 5000 cells/well. After 24 h, the cells were
washed twice with DPBS at either pH 7.4 or pH 7.05. The cells were
incubated (37 C with 5% CO2) in serum-free growth media con-
taining different PP-50 concentrations (0–1000 lg/ml) at pH 7.4
or pH 7.05, for 2 or 24 h. The cells incubated for 2 h were subse-
quently washed with DPBS and incubated for 22 h in growth med-
ia. An MTS assay was performed at the 24 h mark according to the
manufacturer’s instructions.
Cryopreservation and reconstitution
SAOS-2 cells were seeded into 6-well tissue culture plastic
plates (Corning, UK) at 105 cells/well. After 24 h, the cells were
washed with DPBS (pH 7.4), then DPBS (pH 7.05), and were then
incubated (37 C with 5% CO2) in ‘‘incubation media’’: serum-free
media with 0.2 M trehalose, with or without PP-50 at different
concentrations, and water (18.2 MX.cm, Milli-Q filtered, Milli-
pore, USA), at pH 7.05. Following incubation, the osmolarity of all
solutions was adjusted to that of the incubation media using
10  DPBS (PAA, UK) and/or water unless otherwise stated.
After 2 h of incubation (37 C with 5% CO2), the cells were
washed twice with DPBS, and trypsin/EDTA was added at 200 ll/
well. After 15 min of incubation (37 C with 5% CO2), 500 ll/well
growth media was added and the cells were centrifuged at 350g
for 5 min and resuspended in 150 ll of 0.2 M trehalose in FBS. Con-
trols using un-incubated cells were also prepared and resuspended
in FBS (90%) and Me2SO (10%). All samples were transferred into
cryovials (Greiner, UK), and transferred into an isopropanol freez-
ing container (Nalgene, USA), then passively cooled in a 80 C
freezer overnight, before storage in vapour-phase liquid nitrogen
for at least 48 h.
The cells were subsequently thawed by immersing the cryovials
in a 37 C water-bath, after which 850 ll/cryovial of growth media
were slowly added. After centrifugation, the cells were resus-
pended in growth media, and added to the wells of 96-well plates
(100 ll/well). Non-frozen SAOS-2 cells were seeded into the plates
at 5000 cells/well. After 4 h of incubation (37 C with 5% CO2), the
media was changed to growth media of normal osmolarity. MTS
assays were subsequently performed at 24, 48 and 72 h, according
to the manufacturer’s instructions.
td ¼ ðt2  t1Þ ln2
ln Nðt2ÞNðt1Þ
ð1Þ
Nð0Þ ¼ Nð24Þ
2
24
td
ð2Þ
The number of metabolically active cells was found using a stan-
dard curve. The doubling times, td, were calculated using Eq. (1),
where t1 and t2 represent the time at time-points 1 and 2,
respectively, and N(t1) and N(t2) represent the number of cells at
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Fig. 1. Representative fluorescence microscopy images of SAOS-2 cells either fixed
with 4% PFA or incubated with 0.2 M trehalose, 2 mM calcein, with or without PP-
50 (200 lg/ml), at pH 7.05. The cells were subsequently stained with Hoechst
33342 (2 lg/ml) and PI (2 lg/ml) for 15 min, following three washes with DPBS.
The scale bars represent 25 lm.
D.M.C. Sharp et al. / Cryobiology 67 (2013) 305–311 307time-points 1 and 2, respectively. The numbers of proliferative cells
immediately post-thaw were estimated using Eq. (2).
Viability and apoptosis assay
SAOS-2 cells were seeded into 25 cm2 tissue culture flasks
(Corning, UK) at 5  105 cells/flask. After 24 h, the cells were frozen
as described above, scaling volumes appropriately for the growth
area. The freezing protocols used were; 0.2 M trehalose (additional
133 mOsm/l) with or without 25 lg/ml PP-50, and the Me2SO con-
trol. Following thawing of the cells, using a 37 C water-bath, an
Annexin V/PI flow cytometry assay was performed. The manufac-
turer’s instructions were followed, with the modification that for
the cells frozen with trehalose, the osmolarity of all reagents was
adjusted with an additional 133 mOsm/l of sodium chloride. The
samples were examined using a FACScan flow cytometer (Becton
Dickinson, USA).
Statistical analysis
All statistical data analysis was performed using the statistical
software package SPSS 14.0 for Windows. The data for the numbers
of metabolically active cells at 24 h post-thaw, the doubling times
and the flow cytometry data were analysed by one-way ANOVA
followed by Tukey HSD. Values of p < 0.05 were considered to be
statistically significant [45].
All data quoted represent the mean of three repeats ± the stan-
dard error of the mean (SEM), unless otherwise stated.
Results
Calcein and propidium iodide fluorescence assay
Cells incubated in the presence of trehalose and calcein stained
weakly with calcein (Fig. 1). The calcein staining of the cells in the
presence of the cell permeabilising polymer PP-50 was found to be
stronger. For the non-fixed cells, no PI positive cells were observed.
PP-50 toxicity
In the experimental range tested, itwas found that pHhadno sig-
nificant effect on metabolic activity (Fig. 2). PP-50 at 1000 lg/ml
significantly decreased metabolic activity for all incubation condi-
tions tested. For PP-50 concentrations650 lg/ml, there was a small
but statistically significant increase in metabolic activity when the
cells were incubated for 24 h in the presence of the polymer.
Cryopreservation and reconstitution
The number of metabolically active cells present 24 h
post-thaw, was determined from the MTS assay. These data were
normalised by the number of cells present in the pre-freeze
samples, taking dilution into account (Fig. 3). The post-thaw
recovery of the cells incubated with trehalose in the absence
of PP-50 was found to be 68 ± 5%. Of the concentrations tested,
only 25 lg/ml of PP-50 in the pre-freeze incubation media was
found to significantly enhance the cell recovery (103 ± 4%,
p = 0.034). Although the cell recovery was greater in the Me2SO
control group (130 ± 14%), this was found not to be statistically
significant. The fact that this group had a higher 24 h post-thaw
recovery than 100%, may be explained by proliferation of the
cells during the first 24 h. Making the assumption that the dif-
ferent cell doubling times, specific to each treatment group, re-
mained the same throughout the experiment, the number of
viable cells capable of proliferating immediately post-thaw wascalculated to be 64 ± 5% and 70 ± 11% for the PP-50/trehalose
and Me2SO treatments, respectively. Using the same calculation,
the number of proliferative cells for the non-frozen control was
116 ± 6%.
For the freezing protocol involving PP-50 and trehalose, the
osmolarity of the incubation and freezing media was optimised
(Fig. 4). The optimum additional osmolarity was found to be
133 mOsm/l, with a 24 h cell recovery of 91 ± 5%.
The proliferation of the SAOS-2 cells post-thaw was examined
(Fig. 5). It was found that when the concentration of PP-50 in
the incubation media was P50 lg/ml, the cells did not prolifer-
ate at the normal rate compared to cells kept in continuous cul-
ture (non-frozen control). However, when the concentration was
625 lg/ml the growth curves were similar to the non-frozen
control. This was also reflected in the doubling times for the
cells. Although reduced (by 22 ± 2%, p = 0.09) these two groups
were not significantly different from the non-frozen control
(Fig. 6).
In contrast, the cells frozen using Me2SO were found to have an
abnormally high rate of growth. This was also reflected in the dou-
bling time for the cells (Fig. 6), which for this group was signifi-
cantly different from the non-frozen control during the test
period (reduced by 41 ± 4%, p = 0.004).Viability and apoptosis assay
To determine the cell cryosurvival, the post-thaw viability of
the cells was determined by flow cytometry using Annexin V-FITC
and PI staining (Fig. 7). The percentage of viable cells was signifi-
cantly higher for the cells frozen using Me2SO (80 ± 3%) than for
either treatment using trehalose with or without PP-50 (60 ± 2%,
and 44 ± 3%, respectively). The addition of PP-50 at 25 lg/ml dur-
ing the incubation step, significantly enhanced viability (by a factor
of 37 ± 7%, p = 0.002). For all the treatment groups tested, the
majority of the non-viable cells were found to be necrotic rather
than apoptotic.
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Fig. 3. Relationships between cryopreservation treatment and the number of metabolically active cells present 24 h after thawing, normalised by the pre-freeze cell numbers.
These data were derived from three replicates. Statistical differences of the means (p < 0.05) are denoted where the letters differ from one another.
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308 D.M.C. Sharp et al. / Cryobiology 67 (2013) 305–311Discussion
Perhaps the two most important criteria with which different
methods of cell cryopreservation should be judged are; cryosurviv-
al and retention of normal cell processes. The latter is thought to be
particularly important for both research and therapeutic applica-
tions. Here, a Me2SO-free cryopreservation protocol, using treha-
lose delivery utilising PP-50, was developed and assessed. The
cell line SAOS-2 was used as a model for nucleated, adherent hu-
man cells.Calcein and propidium iodide fluorescence assay and PP-50 toxicity
Calcein, like trehalose, is thought to be impermeable to the cell
membrane. Calcein has therefore been used in previous studies to
assess the extent of delivery of hydrophilic species into cells
[10,11]. The degree of calcein uptake in the presence of the PP-
50 was less than that previously reported for the related polymer
PP-75 [10,11]. In part, this may be explained by the presence of tre-
halose in the incubation media in the studies described above. This
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tion of the media, may have decreased the rate of endocytosis for
the cells [34]. Endocytosis has previously been found to play an
important role in the delivery of hydrophilic species into cells
using the related polymer PP-75 [21]. However since the delivery
of trehalose into human erythrocytes which do not perform endo-
cytosis, has previously been demonstrated [27], delivery through
the cell membrane may also be important. It was concluded that
PP-50 was capable of delivering hydrophilic species, such as treha-
lose, into cells. It should be noted that the PP-50 appeared to in-
crease the rate of uptake of hydrophilic species by endocytosis
compared to the control (Fig. 1). In addition to the release of treha-
lose into the cytoplasm, trehalose in endosomes may also have
contributed to the efficacy of the PP-50/trehalose cryopreservation
protocol [33].
Propidium iodide which is incapable of staining cells with intact
cell membranes, has been widely used to assess the viability of
cells [11,28,38]. In the experiments described above, PI staining
was used to determine the viability of the cells, and whether the
membrane permeabilising effect of the PP-50 could be reversed
by washing with pH 7.4 DPBS. Previous studies have found that
the hydrophobicity of PP-50 is strongly affected by pH. The poly-
mer’s ability to bind to the hydrophobic core of cell membranes
is thought to be significantly higher at pH 7.05 than at pH 7.4
[25]. Indeed, this pH change has been found to be sufficient to re-
move PP-50 bound to cell membranes [26]. For the group previ-
ously permeabilised by PP-50, no PI positive cells were observed
(Fig. 1). These data suggest that the permeabilising effect of PP-
50 is reversible and is in agreement with previous studies by Lynch
et al. [26].
The metabolic activity of SAOS-2 cells was assessed after either
a 2 or 24 h challenge with PP-50. This was conducted both at pH
7.05, at which the polymer is thought to have a permeabilising ef-
fect on cell membranes, and pH 7.4, at which the polymer is
thought not to associate with cell membranes. No toxic effect
was observed for PP-50 concentrations 6200 lg/ml. No significant
decrease in metabolic activity was observed for these polymer con-
centrations at both permeabilising and non-permeabilising pHs
(Fig. 2). In addition, no PI positive cells were observed when incu-
bated with PP-50 at 200 lg/ml (Fig. 1). This was in agreement with
previous studies [11,22].
Interestingly, there was a small but statistically significant in-
crease in metabolic activity when the cells were incubated for
310 D.M.C. Sharp et al. / Cryobiology 67 (2013) 305–31124 h in the presence of the polymer. This may be due to the cells
under ‘‘serum starving’’ conditions, metabolising the PP-50. Alter-
natively, the cells may have been more metabolically active in re-
sponse to loss of elements from the cytoplasm, caused by
membrane permeabilisation by the PP-50.
Cryopreservation and reconstitution
Extracellular concentrations of 0.2 M trehalose have previously
been used in the cryopreservation of nucleated mammalian cells
[6,9,15,29]. Since the osmotic coefficient of trehalose in aqueous
solutions is 1.01 [43], 0.2 M trehalose yields an increase in osmo-
larity of approximately 200 mOsm/l. Increasing the normal osmo-
larity of media by more than 200 mOsm/l, can lead to apoptosis
of the majority of cells [13]. Lynch et al. [27] had found that alter-
ing the PP-50 concentration in the presence of trehalose in the
incubation media, determined the resulting intracellular trehalose
loading. The concentration of PP-50 in the incubation media was
therefore altered to determine the polymer concentration leading
to an optimal delivery of trehalose into the cells. Of the concentra-
tions tested, the optimum PP-50 concentration was found to be
25 lg/ml. This was both in terms of the cell recovery at 24 h
post-thaw, and minimising differences in doubling time from the
non-frozen control.
Freezing media consisting of 10% Me2SO and 90% FBS was cho-
sen as the control cryopreservation media. Media such as this has
been widely used in previous studies [23,36,37]. The 24 h cell
recovery for the optimum PP-50 concentration (103 ± 4%) was
found to be less than that for the Me2SO control (130 ± 14%),
although this difference was not statistically significant. In part,
this may be explained by proliferation of the SAOS-2 cells during
the first 24 h post-thaw. Assuming the cell doubling times re-
mained constant throughout the experiment, the number of viable
cells capable of proliferating immediately post-thaw for the PP-50/
trehalose and Me2SO protocols was estimated to be comparable
(64 ± 5% and 70 ± 11%, respectively). This estimated cryosurvival
was similar to that achieved for mesenchymal stem cells by Wang
et al. [42]. Hence the cryosurvival of proliferative cells achieved
using the PP-50/trehalose treatment may have been comparable
to the Me2SO control. It should be noted that MTS assays were
not performed on the cells immediately post-thaw, as the presence
of early apoptotic cells can yield misleading results [24], as could
the presence of cells incapable of substrate attachment.
The cryosurvival immediately post-thaw was tested further for
these protocols, using a flow cytometry based Annexin V/PI assay.
The proportion of viable cells for the PP-50/trehalose and Me2SO
protocols were found to be comparable to those calculated above
(80 ± 3% and 60 ± 2%, respectively). This could indicate that there
is not a significant sub-population of cells for either protocol that
appears viable, but is non-proliferative during subsequent culture.
As discussed previously, Me2SO is currently the cryoprotectant
of choice for most cell culture and therapeutic applications.
Although there is scope for improving the number of cells that sur-
vive the freezing process, the two most concerning problems asso-
ciated with the use of Me2SO are loss of cell functionality, and
toxicity to patients. Therefore, of the outcome measures tested,
the comparison of the cell doubling times to the non-frozen control
was thought to be the more important. It was found that the rate of
proliferation was abnormally high for the cells cryopreserved using
Me2SO compared to non-frozen SAOS-2 cells (Fig. 5). Indeed the
cell doubling times were found to be significantly different from
the non-frozen control by 41 ± 4%. In contrast, the doubling time
for the cells cryopreserved using the optimum PP-50/trehalose
protocol did not significantly affect the doubling time (Fig. 6).
These data suggest that the normal processes of the cells were
affected less when cryopreserved using PP-50/trehalose than Me2-SO, while maintaining high cell recovery. In addition, cells cryopre-
served using this technique, would not contain traces of Me2SO,
and therefore have the potential to reduce the side effects experi-
enced by patients receiving transplants of cryopreserved cells. Sub-
ject to future development and testing, PP-50 mediated delivery of
trehalose into cells could represent an alternative to conventional
cell cryopreservation protocols for both therapeutic and research
applications.Conclusions
In this study, the feasibility of a cellular cryopreservation proto-
col, utilising PP-50 mediated delivery of trehalose into cells, was
assessed using SAOS-2 cells. The concentrations of PP-50, as well
as the osmotic pressure of the incubation and freezing solutions,
were optimised. The optimum PP-50/trehalose cryopreservation
protocol yielded comparable cell recovery at 24 h post-thaw to
cells cryopreserved using Me2SO. Cryopreservation using the PP-
50/trehalose protocol, did not significantly affect the cell doubling
time, in contrast to Me2SO cryopreservation. After future develop-
ment and testing, delivery of trehalose utilising PP-50, could form
the basis of a cryopreservation protocol superior and safer to those
based on Me2SO, for research and therapeutic applications.References
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